Sanctuary Advisors LLC Makes New $1.78 Million Investment in Zimmer Biomet Holdings, Inc. $ZBH

Sanctuary Advisors LLC bought a new position in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH) in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor bought 20,689 shares of the medical equipment provider’s stock, valued at approximately $1,781,000.

A number of other institutional investors and hedge funds have also recently bought and sold shares of the business. DV Equities LLC acquired a new position in shares of Zimmer Biomet during the 4th quarter worth $25,000. Tacita Capital Inc acquired a new stake in shares of Zimmer Biomet in the second quarter valued at about $26,000. Monetary Solutions Ltd purchased a new stake in Zimmer Biomet during the fourth quarter worth about $30,000. Gen Wealth Partners Inc purchased a new stake in Zimmer Biomet during the fourth quarter worth about $31,000. Finally, Elevation Wealth Partners LLC grew its position in Zimmer Biomet by 145.9% during the second quarter. Elevation Wealth Partners LLC now owns 386 shares of the medical equipment provider’s stock worth $33,000 after buying an additional 229 shares during the period. Institutional investors and hedge funds own 88.89% of the company’s stock.

Wall Street Analyst Weigh In

ZBH has been the subject of a number of research reports. Wall Street Zen downgraded shares of Zimmer Biomet from a “buy” rating to a “hold” rating in a research report on Saturday, August 8th. UBS Group restated a “buy” rating and issued a $120.00 price target on shares of Zimmer Biomet in a report on Thursday, August 6th. JPMorgan Chase & Co. reduced their price objective on Zimmer Biomet from $100.00 to $95.00 and set a “neutral” rating for the company in a report on Wednesday, April 29th. Robert W. Baird set a $104.00 target price on Zimmer Biomet in a research report on Thursday, August 6th. Finally, Needham & Company LLC reissued a “hold” rating on shares of Zimmer Biomet in a report on Wednesday, August 5th. One equities research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, thirteen have issued a Hold rating and three have given a Sell rating to the company’s stock. According to MarketBeat, Zimmer Biomet currently has a consensus rating of “Hold” and a consensus target price of $104.42.

Insiders Place Their Bets

In other Zimmer Biomet news, insider Sang Yi sold 5,000 shares of the firm’s stock in a transaction on Friday, May 29th. The stock was sold at an average price of $82.64, for a total transaction of $413,200.00. Following the completion of the transaction, the insider owned 27,251 shares of the company’s stock, valued at approximately $2,252,022.64. This trade represents a 15.50% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Insiders own 1.28% of the company’s stock.

Zimmer Biomet Stock Up 1.2%

Shares of NYSE ZBH opened at $101.41 on Thursday. The firm’s 50-day moving average is $93.40 and its two-hundred day moving average is $91.31. The company has a market capitalization of $19.34 billion, a PE ratio of 24.67, a price-to-earnings-growth ratio of 2.72 and a beta of 0.45. Zimmer Biomet Holdings, Inc. has a 12-month low of $79.12 and a 12-month high of $107.85. The company has a debt-to-equity ratio of 0.50, a current ratio of 1.69 and a quick ratio of 0.94.

Zimmer Biomet (NYSE:ZBH) last issued its quarterly earnings data on Wednesday, August 5th. The medical equipment provider reported $2.07 earnings per share for the quarter, topping analysts’ consensus estimates of $2.01 by $0.06. Zimmer Biomet had a net margin of 9.48% and a return on equity of 13.12%. The business had revenue of $2.18 billion during the quarter, compared to analysts’ expectations of $2.13 billion. During the same period last year, the company posted $2.07 EPS. The company’s revenue was up 4.8% on a year-over-year basis. Zimmer Biomet has set its FY 2026 guidance at 8.470-8.590 EPS. Equities analysts anticipate that Zimmer Biomet Holdings, Inc. will post 8.54 EPS for the current fiscal year.

Zimmer Biomet Company Profile

Zimmer Biomet (NYSE: ZBH) is a global medical device company focused on musculoskeletal healthcare. Headquartered in Warsaw, Indiana, the company designs, manufactures and markets a broad portfolio of products used to treat joint disorders, bone disorders and related conditions. Its customer base includes orthopaedic and dental surgeons, hospitals, ambulatory surgery centers and other healthcare providers that rely on implants, instruments and related services for reconstructive and restorative procedures.

The company’s product offerings span joint replacement systems for hips, knees and shoulders; trauma and extremities implants; spine and thoracic solutions; dental and craniomaxillofacial implants and prosthetics; and sports medicine devices.